Chronic Diseases and Urban Health incorporating the TB case-control platform
Lead Research Organisation:
London School of Hygiene and Tropical Medicine
Department Name: UNLISTED
Abstract
Changes in environment, nutrition, infrastructure, and epidemics has had profound impacts on the health of people worldwide. The impact in developing countries is even more pronounced due to lack of adequate health systems. The TB platform has demonstrated the importance of active cases finding, monitoring, follow up and analysis of exposed contacts on the overall health of the population. The evolution of the platform to chronic diseases and urban health will allow us to upscale this work and better evaluate the requirements for disease monitoring and prevention in The Gambia. The Chronic Diseases and Urban Health platform will support the planned work on non-communicable diseases and emerging health risks for the Unit. Information will be collected on environment, socio-economic status and risk factors related to lifestyle and will therefore work as a ‘targeted’ urban health surveillance system.
Technical Summary
The Chronic Diseases and Urban Health platform will support the planned work on non-communicable diseases and emerging health risks. It will evolve from the current TB Case Contact (TBCC) platform and include existing patients’ cohorts, e.g. rheumatic heart disease, who will be visited at least once a year to collect information on (among others) environment, socio-economic status and risk factors related to lifestyle. This platform will work as a ‘targeted’ urban health surveillance system and possibly develop into an urban HDSS.
The TB case-contact platform was established at MRC in 2001 and allows multi-disciplinary analysis of TB across the spectrum of infection and disease with over 2000 TB cases and 10000 close contacts enrolled to date. The platform has generated over 120 publications including epidemiological, clinical, microbiological, and immunological investigations and is currently recruiting participants for studies on post-TB lung health, a phase III TB vaccine trial, diagnostic and prognostic analysis of TB cases and their contacts and community screening of sub-clinical TB.
The CD&UH platform will include the existing cohorts of TB, chronic liver disease and rheumatic heart disease patients and patients with other chronic diseases such as hypertension, diabetes, and chronic respiratory diseases, e.g. asthma. Patients and their families will be visited at least once a year and data on demographic variables, environment, socio-economic status and risk factors related to lifestyle, health seeking behaviour, etc. will be collected. For each patient in the cohort, we will identify three neighbouring families for which we will collect the same information.
The TB case-contact platform was established at MRC in 2001 and allows multi-disciplinary analysis of TB across the spectrum of infection and disease with over 2000 TB cases and 10000 close contacts enrolled to date. The platform has generated over 120 publications including epidemiological, clinical, microbiological, and immunological investigations and is currently recruiting participants for studies on post-TB lung health, a phase III TB vaccine trial, diagnostic and prognostic analysis of TB cases and their contacts and community screening of sub-clinical TB.
The CD&UH platform will include the existing cohorts of TB, chronic liver disease and rheumatic heart disease patients and patients with other chronic diseases such as hypertension, diabetes, and chronic respiratory diseases, e.g. asthma. Patients and their families will be visited at least once a year and data on demographic variables, environment, socio-economic status and risk factors related to lifestyle, health seeking behaviour, etc. will be collected. For each patient in the cohort, we will identify three neighbouring families for which we will collect the same information.
Publications
Devoid I
(2022)
The household economic burden of drug-susceptible TB diagnosis and treatment in The Gambia.
in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
Jobe D
(2022)
Gene expression in TB disease measured from the periphery is different from the site of infection.
in Tuberculosis (Edinburgh, Scotland)
Sutherland JS
(2022)
Diagnostic Accuracy of the Cepheid 3-gene Host Response Fingerstick Blood Test in a Prospective, Multi-site Study: Interim Results.
in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Nwongbouwoh Muefong C
(2022)
Neutrophils Contribute to Severity of Tuberculosis Pathology and Recovery From Lung Damage Pre- and Posttreatment.
in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Cornell TR
(2023)
Histoplasma Seropositivity in TB Patients in The Gambia: Evidence to Drive Research on a High-Priority Fungal Pathogen.
in Open forum infectious diseases
Richardson TR
(2023)
Field evaluation of a point-of-care triage test for active tuberculosis (TriageTB).
in BMC infectious diseases
Koeppel L
(2023)
Diagnostic performance of host protein signatures as a triage test for active pulmonary TB.
in Journal of clinical microbiology
| Description | STAG-TB |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Participation in a guidance/advisory committee |
| URL | https://www.who.int/groups/strategic-and-technical-advisory-group-for-tuberculosis |
| Description | ENDx-TB |
| Organisation | University of Stellenbosch |
| Country | South Africa |
| Sector | Academic/University |
| PI Contribution | Dr Sutherland is a multi-PI partner with Prof Gerhard Walzl (Stellenbosch) and Prof John Belisle, University of Colarado. Gambia provides access to data from our patient recruitment alongside Dr Sutherland's expertise in immunology and TB diagnostic evaluation. Training of staff in relevant techniques is provided throughout the project period. |
| Collaborator Contribution | Multi-PI team for evaluation of novel diagnostic tests for TB |
| Impact | None to date |
| Start Year | 2020 |
| Description | M72 Epi study |
| Organisation | Gates |
| Country | United States |
| Sector | Private |
| PI Contribution | Site PI for a multi-site epi study |
| Collaborator Contribution | Sponsor for the study |
| Impact | None yet |
| Start Year | 2022 |
| Description | TB Sequel II |
| Organisation | Ludwig Maximilian University of Munich (LMU Munich) |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | MRC is one of the clinical sites and Prof Sutherland is the site-PI and work package lead for host immunological analysis |
| Collaborator Contribution | LMU is the lead PI institution |
| Impact | None yet as the project has only just begun |
| Start Year | 2023 |
| Description | TBVAC-HORIZON |
| Organisation | London School of Hygiene and Tropical Medicine (LSHTM) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Site PI |
| Collaborator Contribution | 30 other sites contributing to development of novel TB vaccines |
| Impact | None to date |
| Start Year | 2023 |
| Description | Triage TB |
| Organisation | University of Stellenbosch |
| Department | Faculty of Medicine and Health Sciences |
| Country | South Africa |
| Sector | Academic/University |
| PI Contribution | Dr Sutherland is a multi-PI partner with Prof Gerhard Walzl (Stellenbosch) and Prof John Belisle, University of Colarado. Gambia provides access to data from our patient recruitment alongside Dr Sutherland's expertise in immunology and TB diagnostic evaluation. Training of staff in relevant techniques is provided throughout the project period. |
| Collaborator Contribution | Dr Sutherland is a multi-PI partner with Prof Gerhard Walzl (Stellenbosch) and Prof John Belisle, University of Colarado. Gambia provides access to data from our patient recruitment alongside Dr Sutherland's expertise in immunology and TB diagnostic evaluation. Training of staff in relevant techniques is provided throughout the project period. |
| Impact | Sutherland et al., CID, 2021 |
| Start Year | 2019 |
| Title | BIOMARKERS FOR DIAGNOSING TUBERCULOSIS |
| Description | A method of diagnosing tuberculosis (TB) is provided. The method comprising the step of testing a biological sample from the subject for the presence of CC4 and at least one other biomarker selected from the group consisting of CC4b, procalcitonin, CCL1, apolipoprotein-CIII, RANTES and TNF-a. A device, kit and computer-implemented method for diagnosing (and optionally also treating) TB are also provided. |
| IP Reference | WO2023057922 |
| Protection | Patent / Patent application |
| Year Protection Granted | 2023 |
| Licensed | No |
| Impact | None to date as it has only just been filed but this is for development of a novel diagnostic test for TB which will have significant health benefit if successful. |
| Description | Evaluation of two point-of-care screening tests for TB |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Other audiences |
| Results and Impact | International symposium presented at the Union World Conference on Lung Health, Paris, November 2023. Presentation was our data from a multi-site trial on evaluation of two novel screening test for TB |
| Year(s) Of Engagement Activity | 2023 |